BIOLASE (NASDAQ:BIOL) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of BIOLASE (NASDAQ:BIOL) in a research note issued to investors on Wednesday. The firm issued a sell rating on the medical technology company’s stock.

BIOLASE Stock Down 14.8 %

Shares of BIOLASE stock opened at $0.01 on Wednesday. The company has a market cap of $250,552.50, a PE ratio of 0.00 and a beta of 0.67. The business has a 50 day moving average of $0.01 and a 200 day moving average of $0.02. BIOLASE has a 52 week low of $0.02 and a 52 week high of $1.94.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.